Varex Imaging Corp Stock News

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

VREX vs. LMAT: Which Stock Is the Better Value Option?

SALT LAKE CITY--( BUSINESS WIRE )--Varex Imaging Corporation (Nasdaq: VREX) announced today that it is scheduled to present at CJS Securities 23rd Annual New Ideas for the New Year virtual investor co

Varex Imaging Corporation (NASDAQ:VREX ) Q4 2022 Earnings Conference Call November 15, 2022 5:00 PM ET Company Participants Christopher Belfiore - Director of Investor Relations Sunny Sanyal - Preside

VAREX IMAGING (VREX) delivered earnings and revenue surprises of 52.38% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Generally speaking, you want to keep your portfolio tied largely to blue-chip stocks.  However, on occasion, your portfolio should also include cheap small-cap stocks.

VREX earnings call for the period ending June 30, 2022.

Varex Imaging Corporation (NASDAQ:VREX ) Q3 2022 Results Conference Call August 2, 2022 5:00 PM ET Company Participants Christopher Belfiore - Director of Investor Relations Sunny Sanyal - President a

SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the third quarter of fiscal year 2022 following the close

Varex Imaging Corporation (NASDAQ:VREX ) Q2 2022 Earnings Conference Call May 3, 2022 5:00 PM ET Company Participants Christopher Belfiore - Director of Investor Relations Sunny Sanyal - President & C

SALT LAKE CITY--(BUSINESS WIRE)--Varex Schedules Second Quarter Fiscal Year 2022 Earnings Release and Conference Call

Varex Imaging (VREX) has announced partial redemption of its 7.875% senior secured notes due 2027.The firm plans to redeem $27M of aggregate principal amount of the notes at a price…

Varex Imaging Corporation (NASDAQ: VREX ) reported Q1 FY22 sales of $198.8 million , up from $177.1 million a year ago and missing the consensus of $208.27 million. Operating cash flow was $11 million. At the end of the first quarter, cash equivalents improved by $13 million sequentially to $158 million. Varex''s revenues decreased 12% sequentially, with both the medical and industrial segments declining from Q4 FY21. Compared to Q1 FY21, total … Full story available on Benzinga.com

Doximity DOCS +20%. Aptevo Therapeutics APVO +17%. Varex Imaging (VREX) -11%. BioCardia (BCDA) -8%.